Ceramide Synthase 6 Impacts T Cell Allogeneic Response and Graft-versus-Host Disease through Regulating N-RAS/ERK Pathway

Investigators found that genetic or pharmacologic targeting of ceramide synthase 6 (CerS6) prevented and reversed chronic graft-vs-host-disease (GVHD). Blockade of CerS6 restrained donor T cells from migrating into GVHD target organs and preferentially reduced activation of donor CD4 T cells.